Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.90 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.90 |
| ▸ | PGR | P06401 | 3/20 | 0.90 |
| ▸ | TSHR | P16473 | 2/20 | 0.90 |
| ▸ | AR | P10275 | 2/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | APEX1 | P27695 | 1/20 | 0.90 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.90 |
| ▸ | IKBKB | O14920 | 1/20 | 0.90 |
| ▸ | CHUK | O15111 | 1/20 | 0.90 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.90 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.90 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.90 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL8508844 | 1.00 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7779 | 1.00 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL6908689 | 1.00 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12099597 | 0.99 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL3456100 | 0.98 | HIF1A (0.86) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL9112497 | 0.98 | HIF1A (0.86) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13740162 | 0.98 | HIF1A (0.86) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL15415155 | 0.97 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL27582183 | 0.97 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL337333 | 0.97 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5942276-A | Method of manufacturing x-ray visible soluble covering | MEDTRONIC, INC. (US) | 1999-08-24 | — | — | US | claimed |
| JP-11279065-A | — | — | None | — | — | JP | disclosed |
| US-20250332427-A1 | ELECTRODES FOR INTRA-CARDIAC PACEMAKER | MEDTRONIC INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12350502-B2 | Electrodes for intra-cardiac pacemaker | MEDTRONIC, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250161213-A1 | OIL-IN-WATER EMULSION WITH AGAR AND DIACETYL TARTARIC ACID ESTERS OF MONO-AND DI-GLYCERIDES (DATEM) | VITUX GROUP AS (NO) | 2025-05-22 | — | — | US | disclosed |
| EP-4486306-A1 | OIL-IN-WATER EMULSION WITH AGAR AND DIACETYL TARTARIC ACID ESTERS OF MONO-AND DI-GLYCERIDES (DATEM) | Vitux Group AS (NO) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180828-A1 | COMPOSITIONS | VITUX GROUP AS (NO) | 2024-06-06 | — | — | US | disclosed |
| EP-4323004-A1 | COMPOSITIONS | Vitux Group AS (NO) | 2024-02-21 | — | — | EP | disclosed |
| EP-4289469-A1 | HEADER ASSEMBLY FOR AN IMPLANTABLE INTRACARDIAC DEVICE AND RESPECTIVE INTRACARDIAC DEVICE | BIOTRONIK SE & Co. KG (DE) | 2023-12-13 | — | — | EP | disclosed |
| CN-112272557-B | System for moulding and coating pharmaceutical tablets | 康蒂纽斯制药公司 | 2023-11-03 | — | — | CN | disclosed |
| US-4953564-A | Screw-in drug eluting lead | MEDTRONIC, INC. (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0138347-B1 | AN IONTOPHORESIS DEVICE | KABUSHIKI KAISYA ADVANCE (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0308572-A2 | An iontophoresis device | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1989-03-29 | — | — | EP | disclosed |
| US-4764164-A | Iontophoresis device | KABUSHIKI KAISYA ADVANCE KAIHATSU KENKYUJO (JP) | 1988-08-16 | — | — | US | disclosed |
| EP-0253901-A1 | SUSTAINED-RELEASE PREPARATION | TEIJIN LIMITED (JP) | 1988-01-27 | — | — | EP | disclosed |
| US-H356-H | EPICARDIAL LEAD HAVING LOW THRESHOLD, LOW POLARIZATION MYOCARDIAL ELECTRODE | MEDTRONIC, INC. (US) | 1987-11-03 | — | — | US | disclosed |
| US-4577642-A | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication | MEDTRONIC, INC. (US) | 1986-03-25 | — | — | US | disclosed |
| EP-0171084-A2 | Pharmaceutical oil-in-water type micro-emulsion | LEDERLE (JAPAN) LTD. (JP) | 1986-02-12 | — | — | EP | disclosed |
| EP-0138347-A1 | An iontophoresis device | KABUSHIKI KAISYA ADVANCE (JP) | 1985-04-24 | — | — | EP | disclosed |
| US-4112073-A | Medicinal composition comprising adrenal cortical hormone and thyroid stimulating hormone releasing hormone | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161213-A1 | OIL-IN-WATER EMULSION WITH AGAR AND DIACETYL TARTARIC ACID ESTERS OF MONO-AND DI-GLYCERIDES (DATEM) | DAGLA, DAGLB, MGLL | NR3C1 3262/4885HIF1A 3380/4885CYP3A4 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.